30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Integra LifeSciences Reports 2Q16 Revenue -

ORTHOWORLD estimates Integra LifeSciences' (IART) 2Q16 orthopaedic revenue at US $27.8MM, +39.1% from 2Q15 as-reported.

ORTHOWORLD estimates 2Q16 segment sales and growth on an as-reported basis, as follows.

  • Joint Reconstruction Extremities $5.7MM, +43.3%
  • Trauma $22.1MM, +38.0%

Joint Reconstruction Extremities growth was led by the Titan Shoulder. Also, within the quarter, IART launched the Fin-Lock™ Glenoid component for the Titan Modular Shoulder system.

Additionally, leadership mentioned strong sales of the Salto Talaris® ankle (acquired from Tornier in 4Q15). Launch of the Cadence™ total ankle is on track, with the first U.S. clinical use and the first ex-U.S. surgery taking place.

Legacy IART lower extremity foot reconstruction product sales were noted to have increased slightly, as well.

Sources: Integra LifeSciences Holdings Corporation; ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.